BioNTech SE 0A3M.IL · Stock Open BioNTech SE in new tab
BioNTech SE Analysis (0A3M.IL)
Is BioNTech SE a good investment? BioNTech SE (0A3M.IL) is currently trading at 116.50 USD. Market analysts have a consensus price target of 219.54 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 6.59. This relatively low multiple may signal that BioNTech SE is undervalued compared to historical market norms.
Investor FAQ
Does BioNTech SE pay a dividend?
No, it does not currently pay a dividend.
What asset class is BioNTech SE?
BioNTech SE is classified as a Stock. You can compare it against 11 other assets in the "Related Symbols" list on this page.
Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
| Year | Total Dividends |
|---|---|
| ▸2022 |
2.13 USD
|
| June 1, 2022 | 2.1322 |
Community Discussion